Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corporate VC Backing Influences Private M&A Step-Ups

This article was originally published in Start Up

Executive Summary

New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.

You may also be interested in...



Corporate Venture "Parents" Rarely Buy Or Partner With Biotech Investments

Based on a five-year analysis of the biopharma investments of SR One, Novartis Venture Funds, and Johnson & Johnson Development Corp., the "parent" entities of these CVC arms rarely, if ever, forge partnerships with their biotech portfolios.

Corporate Investors Boost M&A Step-Ups, But Not IPOs

Corporate venture capital groups have made an impact on life science investing in recent years, but when it comes to going public, the biotechs they back aren’t seeing an extra boost.

Financings Of The Fortnight Ponders The Meaning Of The Best Year For Biotech IPOs Since 2007

Plus news on recent financings by Regulus, Aragon, Antabio and Asceneuron.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel